10-Q: Zai Lab Narrows Losses, Boosts Revenue on Key Product Sales

Zai Lab Limited reported a significant reduction in net loss and increased product revenue for Q2 2025, driven by strong sales of VYVGART and new launches, alongside positive clinical trial advancements.

Summary

• Total revenues for the three months ended June 30, 2025, increased by 9% to $109.98 million, up from $100.50 million in the prior year period.
• Net product revenue grew by 9% to $109.09 million in Q2 2025, compared to $100.11 million in Q2 2024.
• Net loss for Q2 2025 significantly improved, decreasing by 49% to $40.73 million, from $80.28 million in Q2 2024.
• Loss from operations decreased by 28% to $54.90 million in Q2 2025, compared to $76.06 million in Q2 2024.
• For the six months ended June 30, 2025, total revenues increased by 15% to $216.46 million, and net loss improved by 33% to $89.17 million.
• Research and development (R&D) expenses decreased by 18% in Q2 2025 to $50.61 million, and by 4% for the six-month period to $111.34 million, primarily due to resource prioritization and efficiency efforts.
• Selling, general, and administrative (SG&A) expenses decreased by 11% in Q2 2025 to $71.04 million, and by 10% for the six-month period to $134.46 million, also due to efficiency efforts.
• Cash and cash equivalents increased to $732.16 million as of June 30, 2025, from $449.67 million at December 31, 2024.
• Net cash used in operating activities decreased by $39.6 million to $92.72 million for the six months ended June 30, 2025, reflecting improved operational efficiency.
• The company reported significant pipeline advancements, including FDA Fast Track designation for ZL-1310, positive Phase III results for bemarituzumab and Tumor Treating Fields (TTFields), and regulatory filings for repotrectinib.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant reduction in net losses, indicating improved financial efficiency. Key pipeline assets achieved positive clinical milestones and regulatory progress, which are crucial for a biopharmaceutical company's long-term value. While ZEJULA sales faced competitive pressure and the company remains in a net loss position, the overall trajectory and pipeline advancements are positive.

Positives

• Net loss significantly reduced by 49% in Q2 2025 and 33% for the six-month period, indicating improved financial performance.
• Total revenues increased by 9% in Q2 2025 and 15% for the six-month period, driven by strong product sales.
• VYVGART/VYVGART Hytrulo sales increased by 14% in Q2 2025 and 23% for the six-month period, benefiting from extended therapy duration and market penetration.
• NUZYRA sales grew by 16% in Q2 2025 and 32% for the six-month period, supported by increasing market coverage.
• XACDURO and AUGTYRO, launched in Q4 2024, contributed new revenue streams of $4.62 million and $1.40 million respectively in Q2 2025.
• R&D and SG&A expenses decreased due to resource prioritization and efficiency efforts, contributing to reduced operating losses.
• Cash and cash equivalents increased substantially to $732.16 million, providing strong liquidity.
• Net cash used in operating activities decreased, reflecting better cash management and operational efficiency.
• ZL-1310 received FDA Fast Track designation and showed positive Phase Ia/Ib data with clinically meaningful anti-tumor activity (67% objective response rate in 2L SCLC), with a pivotal trial planned for later this year.
• Bemarituzumab's Phase III FORTITUDE-101 trial met its primary endpoint of overall survival in 1L gastric cancer, with regulatory filing planned for China in H2 2025.
• Tumor Treating Fields (TTFields) Phase III PANOVA-3 trial met its primary endpoint of overall survival in pancreatic cancer, with regulatory filing planned for China in H2 2025.
• China's NMPA accepted the supplemental NDA for repotrectinib for NTRK+ solid tumors.
• Preclinical data for ZL-6201 and ZL-1222 demonstrated potent antitumor activity, supporting further clinical development.

Negatives

• ZEJULA sales decreased by 9% in Q2 2025 due to evolving competitive dynamics within the PARPi class.
• OPTUNE sales slightly decreased by 2% in Q2 2025 and 5% for the six-month period.
• Cost of product revenue increased by 22% in Q2 2025 and 18% for the six-month period due to higher sales volumes.
• Interest expenses increased significantly by 157% in Q2 2025 and 305% for the six-month period, primarily due to higher levels of short-term debt.
• The company continues to incur net losses, with an accumulated deficit of $2.54 billion as of June 30, 2025.
• Shareholders' equity decreased to $791.74 million as of June 30, 2025, from $840.90 million at December 31, 2024.

Risks

• Ability to successfully commercialize and generate revenue from approved products.
• Ability to obtain funding for operations and business initiatives.
• Results of clinical and pre-clinical development of product candidates.
• Content and timing of regulatory decisions regarding product candidate approvals.
• Reliance on third parties (licensors, CMOs, CROs, distributors) to carry out contractual duties or meet deadlines.
• Potential issues with Chinese manufacturing facilities conforming to GMPs and passing inspections.
• Inability to obtain or maintain sufficient patent or regulatory data protection for products.
• Changes in U.S. and China trade policies, relations, laws, regulations, and/or sanctions.
• Actions the Chinese government may take to intervene in or influence operations.
• Economic, political, and social conditions in mainland China and governmental policies.
• Significant business disruptions from events outside of control (pandemics, war, natural disasters).
• Uncertainties in the Chinese legal system, including anti-corruption efforts and data/cybersecurity laws.
• Approval, filing, or procedural requirements by Chinese regulatory authorities for issuing securities to foreign investors.
• Violation or liability under U.S. Foreign Corrupt Practices Act or Chinese anti-corruption laws.
• Variations in currency exchange rates and restrictions on currency exchange, particularly RMB conversion.
• Limitations on the ability of Chinese subsidiaries to make payments to the parent company.
• Chinese requirements on residents in mainland China to establish offshore special purpose companies.
• Chinese regulations regarding acquisitions of companies based in mainland China by foreign investors.
• Expiration of, or changes to, financial incentives or discretionary policies granted by local governments in mainland China.
• Restrictions or limitations on the ability of overseas regulators to conduct investigations or collect evidence within mainland China.
• Unfavorable tax consequences if classified as a Chinese resident enterprise for Chinese income tax purposes.
• Failure to comply with applicable Chinese, U.S., and Hong Kong regulations leading to enforcement actions or harm to business.
• Delays or obstacles for closing transactions, such as CFIUS review in investments.
• Inability to renew current leases on desirable terms or locate desirable alternatives for leased properties.

Future Outlook

The company expects product revenue to increase in coming years by expanding patient access to existing commercial products and launching additional products upon regulatory approvals. It anticipates continued significant investments in research and development to advance and expand its pipeline. Financial results are expected to fluctuate based on the success of commercial products and R&D expenses. The company plans to initiate a pivotal trial for ZL-1310 in 2L SCLC later this year and to file for regulatory approval in China for bemarituzumab and Tumor Treating Fields in the second half of 2025. IND-enabling studies for ZL-6201 are also planned for 2025.

Management Comments

• Net product revenue was $109.1 million for the second quarter of 2025, an increase of 9% compared to the prior year period, primarily due to higher sales of VYVGART, driven by an extension of duration of therapy and increasing market penetration, XACDURO, which was launched since the fourth quarter of 2024, and NUZYRA, supported by increasing market coverage and penetration. These higher sales were partially offset by softer sales of ZEJULA, due to evolving competitive dynamics within the PARPi class.
• Developing high quality product candidates requires significant investment in our research and development activities over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area.
• As we pursue our corporate strategic goals, we anticipate that our financial results will fluctuate from quarter to quarter and year to year depending in part on the balance between the success of our commercial products and the level of our research and development expenses.
• We cannot predict whether or when our product candidates will receive regulatory approval. Further, if we receive such regulatory approval, we cannot predict whether or when we may be able to successfully commercialize such products or whether or when such products may become profitable.
• Development and regulatory milestone payments are contingent on the progress of our product candidates prior to commercialization, and we see these payments as favorable because they indicate that product candidates are advancing.
• Sales-based milestone and royalty payments are contingent on the performance of our commercial products, and we see these payments as favorable because they signify that a product is achieving higher sales levels.

Industry Context

Zai Lab operates in the highly competitive biopharmaceutical industry, focusing on oncology, immunology, neuroscience, and infectious disease. The company's strategy involves leveraging its presence in Greater China and the U.S. to develop and commercialize innovative products. The softer sales of ZEJULA highlight the intense competitive dynamics within the PARPi class, while the strong performance of VYVGART and new launches like XACDURO demonstrate successful market penetration in other therapeutic areas. The numerous positive clinical trial readouts and regulatory advancements across its pipeline indicate a strong commitment to R&D and potential for future market expansion, aligning with the industry's focus on innovation and addressing unmet medical needs.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• In January 2025, the company entered into a license agreement with Zenas BioPharma (HK) Limited, from which it obtained a license for a differentiated humanized monoclonal antibody targeting IGF-1R. Mr. Moulder, a member of Zai Lab's Board of Directors, is also the Chairman and CEO of Zenas. An upfront fee of $10.0 million was recorded as research and development expense. The agreement includes potential future development and sales-based milestones of up to $117.0 million and tiered royalties.

Stakeholder Impact

• Shareholders: Potential for increased value due to reduced losses, revenue growth, and significant pipeline advancements, but continued net losses and competitive pressures remain.
• Employees: Resource prioritization and efficiency efforts led to decreases in personnel compensation and related costs, suggesting potential workforce adjustments or tighter cost controls.
• Customers: Continued availability and expansion of commercial products, with new administration options (e.g., VYVGART Hytrulo PFS) offering more flexibility.
• Suppliers/Partners: Ongoing reliance on third-party CROs/CMOs/Investigators, with decreased expenses in these areas for the quarter, but increased licensing fees for new agreements.
• Creditors: Increased short-term debt and new credit facilities indicate reliance on debt financing for working capital, but strong cash position provides comfort.

Next Steps

• Initiate a pivotal trial for ZL-1310 in 2L SCLC later this year (2025).
• File for regulatory approval in China for bemarituzumab in the second half of 2025.
• File for regulatory approval in China for Tumor Treating Fields (TTFields) in the second half of 2025.
• Initiate IND-enabling studies of ZL-6201 as a potential treatment for patients with sarcoma and other LRRC15-positive solid tumors in 2025.
• Continue to focus on increasing patient access to existing commercial products, such as through NRDL listing or increased supplemental insurance coverage.
• Launch additional commercial products upon obtaining required regulatory approvals.

Key Dates

Recommendation

Zai Lab's Q2 2025 filing demonstrates significant progress on multiple fronts. The substantial reduction in net loss and operating loss, coupled with robust revenue growth driven by key commercial products like VYVGART and successful new launches, indicates improving financial health and operational efficiency. More critically for a biopharmaceutical company, the pipeline advancements are highly compelling: FDA Fast Track designation for ZL-1310, positive Phase III data for bemarituzumab and Tumor Treating Fields, and multiple regulatory filings signal strong clinical execution and potential for future market expansion. While ZEJULA faces competitive headwinds and the company is not yet profitable, the positive momentum in both commercial performance and pipeline development suggests a favorable long-term outlook for investors willing to tolerate the inherent risks of the biotech sector.

Keywords

Biopharmaceutical, Oncology, Immunology, Neuroscience, Infectious Disease, SEC Filing, 10-Q, Clinical Trials, Drug Development, Commercialization, Zai Lab, ZEJULA, VYVGART, NUZYRA, OPTUNE, QINLOCK, XACDURO, AUGTYRO, ZL-1310, Bemarituzumab, Tumor Treating Fields, Repotrectinib, ZL-6201, ZL-1222, Efgartigimod, ZL-1503, China Market, FDA Fast Track, NMPA Approval